Interview with Henning Fahrenkamp, Chairman of Board of Directors, BPI
29.09.2009
Related Interviews
Christian Conrad – Senior Patient Engagement Manager, Novartis Oncology…
Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer…
Interview with Elmar Schnee , President of Merck Serono and Member of the…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
CAR-T in Europe / EBMT's Nicolaus Kröger on GoCART Coalition & EU Harmonisation
Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow Transplantation (EBMT) outlines the progress made by the multi-stakeholder GoCART…
APAC / IFPMA's Thomas Cueni on the Value of Business Ethics for SMEs during COVID-19
Drawing on the findings of the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and…
Global / Astellas CMO Bernie Zeiher: Leaving No Stone Unturned in the Quest for Patient Value
Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some…
Vaccine Nationalism / “Moral Obscenity, Public Health Catastrophe & Economic Folly”
Over two years since the first cases of COVID-19, the world is still coming to terms with the virus. While vaccines have been developed and rolled out in record time…
Latest Report
